English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/209767
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance

AuthorsGarcía-Marco, José A.; López Jiménez, Javier; Recasens, Valle; Fernández Zarzoso, Miguel; González-Barca, Eva; Somolinos De Marcos, Nieves; Ramírez, M. José; Peñalver, Francisco-Javier; Yáñez, Lucrecia; Serna, Javier de la; García-Malo, Mª Dolores; Debén, Guillermo; Ruiz Guinaldo, M. Angeles; Paz Arias, Raquel De; Bañas Llanos, Elena; Jarque, Isidro; Fernández Valle, M. del Carmen; Carral, Anna; Pérez De Oteyza, Jaime; Donato Martin, Eva María; Pérez Fernández, Inmaculada; Martínez, Rafael; Andreu Costa, M. Angeles; Champ, Diana; García Suarez, Julio; González, Marcos ; Ferrer, Secundino; Carbonell, Félix; García-Vela, José A.
Issue DateNov-2019
PublisherFerrata Storti Foundation
CitationHaematologica 104(11): 2249-2257 (2019)
AbstractIt has been postulated that monitoring measurable residual disease (MRD) could be used as a surrogate marker of progression-free survival (PFS) in chronic lymphocytic leukemia (CLL) patients after treatment with immunochemotherapy regimens. In this study, we analyzed the outcome of 84 patients at 3 years of follow-up after first-line treatment with fludarabine, cyclophosphamide and rituximab (FCR) induction followed by 36 months of rituximab maintenance thearpy. MRD was assessed by a quantitative four-color flow cytometry panel with a sensitivity level of 10-4. Eighty out of 84 evaluable patients (95.2%) achieved at least a partial response or better at the end of induction. After clinical evaluation, 74 patients went into rituximab maintenance and the primary endpoint was assessed in the final analysis at 3 years of follow-up. Bone marrow (BM) MRD analysis was performed after the last planned induction course and every 6 months in cases with detectable residual disease during the 36 months of maintenance therapy. Thirty-seven patients (44%) did not have detectable residual disease in the BM prior to maintenance therapy. Interestingly, 29 patients with detectable residual disease in the BM after induction no longer had detectable disease in the BM following maintenance therapy. After a median followup of 6.30 years, the median overall survival (OS) and PFS had not been reached in patients with either undetectable or detectable residual disease in the BM, who had achieved a complete response at the time of starting maintenance therapy. Interestingly, univariate analysis showed that after rituximab maintenance OS was not affected by IGHV status (mutated vs. unmutated OS: 85.7% alive at 7.2 years vs. 79.6% alive at 7.3 years, respectively). As per protocol, 15 patients (17.8%), who achieved a complete response and undetectable peripheral blood and BM residual disease after four courses of induction, were allowed to stop fludarabine and cyclophosphamide and complete two additional courses of rituximab and continue with maintenance therapy for 18 cycles. Surprisingly, the outcome in this population was similar to that observed in patients who received the full six cycles of the induction regimen. These data show that, compared to historic controls, patients treated with FCR followed by rituximab maintenance have high-quality responses with fewer relapses and improved OS. The tolerability of this regime is favorable. Furthermore, attaining an early undetectable residual disease status could shorten the duration of chemoimmunotherapy, reducing toxicities and preventing long-term side effects. The analysis of BM MRD after fludarabine-based induction could be a powerful predictor of post-maintenance outcomes in patients with CLL undergoing rituximab maintenance and could be a valuable tool to identify patients at high risk of relapse, influencing further treatment strategies.
Description© 2019 Ferrata Storti Foundation.
Publisher version (URL)http://dx.doi.org/10.3324/haematol.2018.204891
URIhttp://hdl.handle.net/10261/209767
DOI10.3324/haematol.2018.204891
ISSN0390-6078
E-ISSN1592-8721
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
High_Garcia_Marco_Art2019.pdf2,46 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.